Duluth Holdings ( DLTH ) reported sales fell 4.1% year over year to $98.6M in Q1. Direct-to-consumer sales were down 8.7% to $57.1M due to declines in web traffic and web conversion due to reduced promotional activity partially offset by higher average order values. Meanwhile, retail store sales increased by 3.3% to $41.5M, driven by higher average order values in comparable stores, coupled with t...
Duluth Holdings ( DLTH ) reported sales fell 4.1% year over year to $98.6M in Q1. Direct-to-consumer sales were down 8.7% to $57.1M due to declines in web traffic and web conversion due to reduced promotional activity partially offset by higher average order values. Meanwhile, retail store sales increased by 3.3% to $41.5M, driven by higher average order values in comparable stores, coupled with two new stores opened in the third quarter of 2025. CEO Stephanie Pugliese said customers are responding positively to core products, seasonal prints and patterns, and the newest marketing campaign. The retailer saw gross margin expand by 540 basis points to 57.4% of sales during the quarter. The increase in gross margin rate was primarily driven by an increase in average unit retail prices from reduced promotional activity, coupled with an improvement in product costs from the direct-to-factory sourcing initiative, partially offset by tariff costs. Non-GAAP EPS was reported at -$0.20 vs. -$0.39 consensus and -$0.44 a year ago. On the balance sheet, Duluth Holdings ( DLTH ) ended the quarter with $6.1M of cash and cash equivalents, $62.3M of net working capital, and $6.0M in outstanding debt on the $100.0M asset-based lending facility, resulting in approximately $100M of net liquidity. Looking ahead, Duluth Holdings ( DLTH ) sees FY26 sales landing in a range of $540M to $560M (midpoint $550M) vs. the consensus estimate of $555.6M. "O ur focus remains on delivering the core, high-quality, solution-based products that resonate most with our customers and creating an exceptional experience," stated Pugliese. Shares of Duluth Holdings ( DLTH ) were up 1.8% in premarket trading to $3.38 vs. the 52-week range of $1.82 to $4.66. More on Duluth Holdings Duluth Holdings Still Needs To Prove Itself Duluth Holdings: Showing Signs Of Stabilization Duluth Holdings Inc. (DLTH) Q4 2025 Earnings Call Transcript Duluth Holdings Non-GAAP EPS of -$0.20 beats by $0.19, revenue of $98.59M beats...
(RTTNews) - Brady Corp. (BRC), a developer and manufacturer of specialty products, on Monday announced that it appointed current board member Vineet Nargolwala as Chief Executive Officer, effective June 8.
(RTTNews) - Brady Corp. (BRC), a developer and manufacturer of specialty products, on Monday announced that it appointed current board member Vineet Nargolwala as Chief Executive Officer, effective June 8.
Incyte ( INCY ) has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25B. Star Therapeutics will be eligible to receive up to $750M in additional payments upon the achievement of sales milestones, for a total potential consideration of up to $2B, subject to customary closing adjustments. The proposed acquisition would add VGA0...
Incyte ( INCY ) has entered into a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for $1.25B. Star Therapeutics will be eligible to receive up to $750M in additional payments upon the achievement of sales milestones, for a total potential consideration of up to $2B, subject to customary closing adjustments. The proposed acquisition would add VGA039, a novel monoclonal antibody, to Incyte’s hematology portfolio. VGA039 has the potential to be a universal hemostatic therapy that can treat numerous bleeding disorders, starting with all types of von Willebrand disease. The drug has advanced into a Phase 3 study designed to investigate the safety and efficacy of subcutaneous administration of VGA039 as prophylaxis for bleeding in patients with every type of von Willebrand disease. It has received fast track, orphan drug, rare pediatric disease, and breakthrough therapy designations from the U.S. Food and Drug Administration. “VGA039 fits directly into our strategy of building a top-tier growth company for the future,” said Bill Meury, CEO of Incyte. “It is a first-in-class, Phase 3 asset with compelling early data, a manageable development path and the potential to become an important new growth driver in one of our core therapeutic areas – hematology. The transaction has all of the attributes we look for in business development opportunities.” The transaction is an equity acquisition and is expected to close in the third quarter of 2026, pending Hart-Scott-Rodino review resulting in an expected R&D charge of approximately $1.25B that will be included in third quarter and full year 2026 GAAP and non-GAAP results. More on Incyte Incyte Corporation (INCY) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript Incyte Corporation (INCY) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript Incyte: Strong Business, But Risks Remain Incyte nears $2B deal for blood diso...
Volato Group ( SOAR ) has signed a definitive agreement for a $2.2M strategic equity investment. The restricted common stock placement was led by medical technology firm Catheter Precision ( VTAK ) alongside other institutional technology investors. The capital injection significantly strengthens Volato’s balance sheet following the termination of its previously announced transaction with M2i Glob...
Volato Group ( SOAR ) has signed a definitive agreement for a $2.2M strategic equity investment. The restricted common stock placement was led by medical technology firm Catheter Precision ( VTAK ) alongside other institutional technology investors. The capital injection significantly strengthens Volato’s balance sheet following the termination of its previously announced transaction with M2i Global. Management confirmed that the M2i termination will not disrupt its ability to pursue milestones under its accepted NYSE American compliance plan. The capital from this round will back Volato’s core strategic shift toward the artificial intelligence ecosystem, specifically targeting potential mergers and acquisitions (M&A) across AI software, data infrastructure, compute, and power generation sectors. Volato revealed it has already received two unsolicited, non-binding letters of intent regarding potential transactions involving AI data center infrastructure and dedicated power generation assets. The company already operates Parslee, an AI software platform specializing in document intelligence, and is actively developing Volato AI to deploy specialized AI agents into the aviation sector. Following the placement, Catheter Precision becomes Volato’s largest shareholder. The strategic investment remains subject to customary closing conditions, including the authorization of a supplemental listing application filed by Volato with the NYSE American exchange. More on Catheter Precision, Volato Group Volato Group receives NYSE American acceptance of compliance plan Volato Group uses full ATM capacity; convertible debt hits zero ahead of M2i merger Historical earnings data for Catheter Precision Financial information for Catheter Precision Financial information for Volato Group
(RTTNews) - Shares of Tate & Lyle Plc were gaining around 14 percent on the London Stock Exchange after the British sweetener and food solutions firm announced Monday its agreement to a 595 pence per share all-cash deal to be bought by U.S. food ingredients maker Ingredion Inc. T
(RTTNews) - Shares of Tate & Lyle Plc were gaining around 14 percent on the London Stock Exchange after the British sweetener and food solutions firm announced Monday its agreement to a 595 pence per share all-cash deal to be bought by U.S. food ingredients maker Ingredion Inc. T
U.S. government acquires an ownership stake in Intel (NasdaqGS:INTC) under the Trump administration. Transaction is part of a broader federal approach to take equity stakes in key AI and semiconductor companies. Move goes beyond prior grants and subsidies, introducing direct public sector participation in Intel's capital structure. Intel, traded on the NasdaqGS under the ticker INTC, is a major U....
U.S. government acquires an ownership stake in Intel (NasdaqGS:INTC) under the Trump administration. Transaction is part of a broader federal approach to take equity stakes in key AI and semiconductor companies. Move goes beyond prior grants and subsidies, introducing direct public sector participation in Intel's capital structure. Intel, traded on the NasdaqGS under the ticker INTC, is a major U.S. semiconductor and AI hardware company. Federal ownership adds a new layer to an already high...
Two Hongkongers have been sentenced to life imprisonment for murdering a man by suffocating him with tape in a village temple and burying his body under concrete outside, with a judge describing the killing as hideous “beyond words”. High Court Judge Anthony Kwok Kai-on handed down the mandatory sentences to Chan Wah-hing, 67, and Chan Yiu-lung, 33, on Monday after they were earlier convicted of m...
Two Hongkongers have been sentenced to life imprisonment for murdering a man by suffocating him with tape in a village temple and burying his body under concrete outside, with a judge describing the killing as hideous “beyond words”. High Court Judge Anthony Kwok Kai-on handed down the mandatory sentences to Chan Wah-hing, 67, and Chan Yiu-lung, 33, on Monday after they were earlier convicted of murdering a 51-year-old man over a financial dispute in September 2022 and disposing of his body near...
Luis Alvarez/DigitalVision via Getty Images Nexus Industrial REIT ( NXR.UN:CA ) is a Canadian-based REIT and publicly traded on the TSX. Back in early 2026, I wrote about this company and gave a buy recommendation. Fast forward to today, and I am changing my position to a strong buy. Management initiated this turnaround more than 2 years ago, and over the past 6 months, it has improved its finance...
Luis Alvarez/DigitalVision via Getty Images Nexus Industrial REIT ( NXR.UN:CA ) is a Canadian-based REIT and publicly traded on the TSX. Back in early 2026, I wrote about this company and gave a buy recommendation. Fast forward to today, and I am changing my position to a strong buy. Management initiated this turnaround more than 2 years ago, and over the past 6 months, it has improved its finances amid an economic slowdown. This shows the company is in good hands; if management can improve its bottom line during an economic slowdown, it can outperform in any economy. Nexus Industrial REIT's Milestones April 2026, DBRS issued a BBB investment grade rating on Nexus Industrial REIT's $500M senior unsecured debentures. The newly issued debentures are used to repay its more expensive debt. This is a credit rating improvement and lowers the overall interest costs on its debt. Q1-2026 marked the first time in 10 quarters that management was able to lower its dividend payout ratio to sub 100%. Management further reiterated its confidence that a dividend payout ratio below 100% is achievable. Same property NOI had improved to $30.0, an improvement of 2.8% 2 new industrial assets from Montreal were added to the portfolio New leasing activity resulted in 1,218,516 sf leased up with an average spread of 60% improvement over existing in-place and expiring rents Nexus Industrial REIT Stock Price Continues to be Undervalued Based on Nexus Industrial REIT's Q1-2026, its portfolio-wide cap rate is 5.94%. Using its annual dividends of $0.64, this implies its stock price should be valued at $10.77; the stock price is currently trading at $7.82, implying there is an almost $3 discount today. Looking at it through a different lens, in applying the PE ratio, Nexus Industrial REIT currently trades at a relatively cheaper ratio than the 2 other industrial competitors: Google Finance and Financial Statements One of the reasons Nexus Industrial REIT trades at a relatively large discount is ...
Croatia head coach says England game crucial to hopes Kovacic, Gvardiol and Modric lacking match sharpness Zlatko Dalic sees Croatia’s World Cup opener against England as pivotal to their summer fortunes, admitting a softer first match may have been preferable for a team struggling with form and fitness issues. Croatia beat Slovenia 2-1 in their final friendly before flying to the US but Dalic is ...
Croatia head coach says England game crucial to hopes Kovacic, Gvardiol and Modric lacking match sharpness Zlatko Dalic sees Croatia’s World Cup opener against England as pivotal to their summer fortunes, admitting a softer first match may have been preferable for a team struggling with form and fitness issues. Croatia beat Slovenia 2-1 in their final friendly before flying to the US but Dalic is likely to face several selection issues when they face England on 17 June. The Manchester City pair of Mateo Kovacic and Josip Gvardiol are both coming back from injury and it adds to the sense that Dalic’s side, who finished third in 2022 and runners-up four years earlier , risk starting their tournament on the back foot. Continue reading...